References of "Silverman, S"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAn algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
Bruyère, Olivier ULg; Cooper, C; Pelletier, JP et al

in Seminars in Arthritis & Rheumatism (2014), 44

Objectives: Existing practice guidelines for osteoarthritis (OA) analyze the evidence behind each proposed treatment but do not prioritize the interventions in a given sequence. The objective was to ... [more ▼]

Objectives: Existing practice guidelines for osteoarthritis (OA) analyze the evidence behind each proposed treatment but do not prioritize the interventions in a given sequence. The objective was to develop a treatment algorithm recommendation that is easier to interpret for the prescribing physician based on the available evidence and that is applicable in Europe and internationally. The knee was used as the model OA joint. Methods: ESCEO assembled a task force of 13 international experts (rheumatologists, clinical epidemiologists, and clinical scientists). Existing guidelines were reviewed; all interventions listed and recent evidence were retrieved using established databases. A first schematic flow chart with treatment prioritization was discussed in a 1-day meeting and shaped to the treatment algorithm. Fine-tuning occurred by electronic communication and three consultation rounds until consensus. Results: Basic principles consist of the need for a combined pharmacological and non-pharmacological treatment with a core set of initial measures, including information access/education, weight loss if overweight, and an appropriate exercise program. Four multimodal steps are then established. Step 1 consists of background therapy, either non-pharmacological (referral to a physical therapist for re-alignment treatment if needed and sequential introduction of further physical interventions initially and at any time thereafter) or pharmacological. The latter consists of chronic Symptomatic Slow-Acting Drugs for OA (e.g., prescription glucosamine sulfate and/or chondroitin sulfate) with paracetamol at-need; topical NSAIDs are added in the still symptomatic patient. Step 2 consists of the advanced pharmacological management in the persistent symptomatic patient and is centered on the use of oral COX-2 selective or non-selective NSAIDs, chosen based on concomitant risk factors, with intra-articular corticosteroids or hyaluronate for further symptom relief if insufficient. In Step 3, the last pharmacological attempts before surgery are represented by weak opioids and other central analgesics. Finally, Step 4 consists of end-stage disease management and surgery, with classical opioids as a difficult-to-manage alternative when surgery is contraindicated. Conclusions: The proposed treatment algorithm may represent a new framework for the development of future guidelines for the management of OA, more easily accessible to physicians. © 2014 The Authors. [less ▲]

Detailed reference viewed: 21 (5 ULg)
Full Text
Peer Reviewed
See detailLong-term fracture rates seen with continued ibandronate treatment : pooled analysis of DIVA and MOBILE long-term extension studies
Miller, PD; Recker, RR; Harris, S et al

in Osteoporosis International (2014), 25(1), 349-357

Detailed reference viewed: 34 (3 ULg)
Full Text
Peer Reviewed
See detailIbandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.
Cranney, Ann; Wells, G. A.; Yetisir, E. et al

in Osteoporosis International (2009), 20(2), 291-7

SUMMARY: This analysis was conducted to assess the effect of high versus lower doses of ibandronate on nonvertebral fractures. The results were adjusted for clinical fracture, age, and bone density. The ... [more ▼]

SUMMARY: This analysis was conducted to assess the effect of high versus lower doses of ibandronate on nonvertebral fractures. The results were adjusted for clinical fracture, age, and bone density. The treatment effect was dose-dependent. Higher doses of ibandronate significantly reduced the risk of nonvertebral fractures more effectively compared with lower doses. INTRODUCTION: The objective of this study was to assess the efficacy of different doses of ibandronate on nonvertebral fractures in a pooled analysis. METHODS: Eight randomized trials of ibandronate were reviewed for inclusion. Alternative definitions of high versus low doses based on annual cumulative exposure (ACE) were explored. A time-to-event analysis was conducted using Kaplan-Meier methodology. Hazard ratios (HR) were derived using Cox regression and adjusted for covariates. RESULTS: Combining higher ACE doses of > or = 10.8 mg (150 mg once monthly, 3 mg i.v. quarterly, and 2 mg i.v. every 2 months) versus ACE doses of 5.5 mg, from two trials, resulted in an HR 0.62 (95% CI 0.396-0.974, p = 0.038). There was a dose-response trend with increasing ACE doses (7.2-12 mg) versus ACE of 5.5 mg. CONCLUSIONS: A dose-response effect on nonvertebral fractures was observed when comparing high with low ACE doses. A significant reduction in nonvertebral fractures was noted when pooling data from trials using ACE doses of > or = 10.8 mg versus ACE < or = 7.2 mg; and with ACE > or = 10.8 mg versus ACE of 5.5 mg (38% reduction). Higher ibandronate dose levels (150 mg monthly or 3 mg i.v. quarterly) significantly reduced nonvertebral fracture risk in postmenopausal women. [less ▲]

Detailed reference viewed: 67 (4 ULg)
Full Text
Peer Reviewed
See detailFracture efficacy of monthly ibandronate and weekly bisphosphonate therapy: a retrospective cohort study
Reginster, Jean-Yves ULg; Blumentals, W.; Barr, C. et al

in Osteoporosis International (2008, April), 19(Suppl.1), 9

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailRisedronate significantly reduces hip fracture risk in elderly women with osteoporosis
Bensen, W; Piette, F; Ettinger, M et al

in Journal of Bone and Mineral Research (2000), 15(S1), 226

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailRisedronate reduces hip fracture risk in elderly women with osteoporosis with a rapid and sustained effect
Silverman, S; Geusens, P; Bensen, W et al

in Arthritis and Rheumatism (2000), 43(S1), 781

Detailed reference viewed: 11 (1 ULg)